healthcare-thumbnail.png

Antibody-Drug Conjugates (ADCs) in oncology market Research Report

Published: 2025 - January

Report Code: VMR-17713

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Antibody-Drug Conjugates (ADCs) in oncology Market Analysis

The Antibody-Drug Conjugates (ADCs) in oncology market refers to a class of targeted cancer therapies that combine monoclonal antibodies with potent cytotoxic agents. These agents are designed to selectively deliver the cytotoxic drug to cancer cells, minimizing damage to healthy cells. ADCs offer high specificity and improved therapeutic outcomes, representing a paradigm shift in cancer treatment.

Disruptive Impact and Opportunities:

ADCs are transforming oncology treatment paradigms by offering precision therapies that are both targeted and effective. Their ability to deliver cytotoxic agents directly to tumor cells without affecting surrounding healthy tissues presents significant opportunities in terms of improving patient outcomes and reducing adverse side effects. ADCs also provide new treatment options in cancers that were previously hard to treat. The market potential is considerable, with a focus on new, safe, easy-to-administer therapies that promise substantial efficacy. ADCs are poised to address unmet needs across a range of cancers, from breast and lung cancers to lymphomas and hematological malignancies.

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - Emerging Drugs

  • Teliso-V

  • Telisotuzumab vedotin

  • NBE-002

  • Ladiratuzumab Vedotin

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - Marketed Drugs

  • Disitamab vedotin (RC48) + PD1

  • SHR-A1811 + pyrotinib maleate

  • ARX788 + pyrotinib maleate

  • Zynlonta

Key Companies:

  • Seagen

  • AstraZeneca

  • Daiichi Sankyo

  • Merck

  • RemeGen

  • Jiangsu-Hengrui Medicine

  • Zhejiang Medicine/NovoCodex

  • NBE-Therapeutics

  • ImmunoGen Inc.

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - By Type

·  Monoclonal Antibodies (mAbs)

  • HER2-targeted ADCs

  • CD30-targeted ADCs

  • CD33-targeted ADCs

  • Other mAb-targeted ADCs

·  Linker Technology

  • Cleavable Linkers

  • Non-Cleavable Linkers

·  Payloads (Cytotoxic Drugs)

  • Maytansinoid-based Payloads

  • Auristatin-based Payloads

  • Calicheamicin-based Payloads

  • Duocarmycin-based Payloads

  • Other Cytotoxic Agents

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - By Administration Type

·  Intravenous (IV) Administration

  • Standard Infusion

  • Extended Infusion

·  Subcutaneous (SC) Administration

·  Oral Administration

What’s in It for You?

  • Gain insights into emerging ADC therapies poised to disrupt oncology treatment landscapes.

  • Understand competitive dynamics with a detailed overview of key players and their strategies.

  • Identify market opportunities based on emerging drugs and evolving treatment paradigms.

  • Anticipate market trends and plan for future investment and R&D directions.

  • Access a comprehensive analysis of drug candidates currently in development and their market potential.

  1. Antibody–drug Conjugates (ADCs) in Oncology Market - Executive Summary

    1. Introduction

    2. Objectives

    3. Key Findings

      1. Market Size 2025 & 2030: By Key Country (10MM)

      2. Global Market Size 2025 & 2030: By Key Segment

      3. Key Investments & Startup Analysis

    4. Research Methodology

  2. Understanding the Disease

    1. Disease Overview

    2. Classification

    3. Signs and Symptoms

    4. Risk Factors

    5. Causes

    6. Disease Biology & Digital Innovations

    7. Stages & Staging System

    8. Diagnostic Algorithm

    9. Current Treatment Practices & Algorithm

    10. Current Standard of Care and Treatment Gaps

    11. Patient Demographics and Treatment Pathways

  3. Guidelines

  4. Unmet Needs

  5. Epidemiology and Patient Population

    1. Epidemiology Key Findings

    2. Assumptions and Rationale: 10MM

    3. Epidemiology Scenario: 10MM

    4. U.S. Epidemiology Scenario

    5. EU-5 Epidemiology

      1. U.K. Epidemiology Scenario

      2. Germany Epidemiology Scenario

      3. France Epidemiology Scenario

      4. Italy Epidemiology Scenario

      5. Spain Epidemiology Scenario

    6. Japan Epidemiology Scenario

    7. China Epidemiology Scenario

    8. Australia Epidemiology Scenario

    9. India Epidemiology Scenario   

  6. Real-world Data & Real-world Evidence

  7. Drug Development Landscape

    1. Existing Key Drug Candidate Profiles/ Marketed Therapies

    2. Competitive Analysis and Differentiation

    3. Overview of Similar/Competing Drugs in Clinical Trials

    4. Future Trends and Emerging Drugs

  8. Regulatory Strategy and Potential Challenges

    1. Regulatory Pathways in Key Markets

    2. Anticipated Regulatory Hurdles and Mitigation Strategies

    3. Case Studies in Oncology Drug Regulation

    4. Impact of Potential Changes to Regulatory Framework

  9. Commercial Landscape

    1. Market Size & Growth Rates

    2. Key Approvals & Anticipated Loss of Exclusivity

    3. PESTLE & Porter’s Five Forces Analysis

    4. Market Shares, Positioning/Ranking

    5. Market Drivers

    6. Identification of Threats

    7. Digital Evolution in Commercialization

  10. Market Segmentation

  11. Pricing, Reimbursement, and Access

    1. Competitive Pricing Analysis

    2. Reimbursement Landscape and Challenges

    3. Strategies for Market Access and Equity

    4. Patient Spending/Expenditure Analysis

  12. Future Trends, Disruptions, and Opportunities

    1. Analysis of Emerging Trends

    2. Technological Impact

    3. Impact of Potential Market Disruptors

    4. Opportunities for Future Development and Expansion

    5. Considerations for Investment Opportunities

  13. Global Market Dynamics

    1. Regional Regulatory Disparities

    2. Cross-Border Partnership Strategies

    3. Global Supply Chain Dynamics

    4. Case Studies: Success and Failure in Global Markets

    5. Strategies for Global Expansion and Localization

  14. Company Profiles

 

 

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.